Lou Bueno / Flickr cc
The authors of a new study on the timing of antibiotic administration in women undergoing cesarean section say the findings suggest current recommendations should be re-evaluated.
The study, published today in
Antimicrobial Resistance and Infection Control, looked at the rate of surgical-site infections (SSIs) in more than 55,000 pregnant women undergoing cesarean section deliveries who received antibiotics either before the incision, as is currently recommended by the World Health Organization (WHO), or after umbilical cord clamping. The results showed no difference in SSIs between the two groups.
Timing of antibiotics questioned
In the study, researchers from Bern University Hospital in Switzerland, Swissnoso, the Swiss National Center for Infection Control, and Rutgers University analyzed data on 55,901 women who underwent cesarean section at 75 Swiss hospitals from 2009 to 2018. The aim of the study, the largest of its kind to date, was to assess the a
Swiss doctors limit remdesivir use as government looks to procure more
US firm Gilead set the price for remdesivir at CHF380.50 per dose for developed countries. Multiple doses are a typical treatment course. Mtva - Media Service Support And Asset Management Fund
Swiss doctors are taking a cautious approach to the use of remdesivir for treating Covid-19 in the midst of emerging evidence from the World Health Organisation on the drug s ineffectiveness. Yet, the Swiss authorities moved ahead with an authorisation of the treatment and are making efforts to procure more of it.
This content was published on December 10, 2020 - 11:00
Swiss doctors limit remdesivir use as government looks to procure more
US firm Gilead set the price for remdesivir at CHF380.50 per dose for developed countries. Multiple doses are a typical treatment course. Mtva - Media Service Support And Asset Management Fund
Swiss doctors are taking a cautious approach to the use of remdesivir for treating Covid-19 in the midst of emerging evidence from the World Health Organisation on the drug s ineffectiveness. Yet, the Swiss authorities moved ahead with an authorisation of the treatment and are making efforts to procure more of it.
This content was published on December 10, 2020 - 11:00